Market Research Logo

Generic Drugs Market Forecast 2018-2028

Generic Drugs Market Forecast 2018-2028

The generic drugs market is estimated at $257.3bn in 2017 and is expected to grow at a CAGR of 7.9% from 2017 to 2028. The generic drugs market is expected to grow at a CAGR of 7.2% in the second half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 254page report you will receive 66 tables and 84 figures– all unavailable elsewhere.

The 254page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brandnew report today you stay better informed and ready to act.

Report Scope

  • Generic Drugs Market forecasts from 20182028
  • Generic Drugs Regional Market and National Market forecasts from 20182028, covering:
  • North America: US & Canada
  • Europe: Germany, UK, France, Italy, Spain, Rest of Europe
  • AsiaPacific: Japan, Australia, India, China, South Korea, Rest of AsiaPacific
  • Middle East & Africa: South Africa, Saudi Arabia, U.A.E, Rest of Middle East & Africa
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • SWOT Analysis and Porter’s Five Forces Analysis of the generic drugs market.
  • Assessment of selected leading companies that hold major market shares in the generic drugs market.
  • Teva
  • Novartis (Sandoz)
  • Allergan
  • Mylan
  • Pfizer
  • Abbott
  • Sun Pharma
  • Aspen
  • Fresenius Kabi
  • Sanofi
  • Dr. Reddy’s Laboratories
  • Apotex
Visiongain’s study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (nonprintable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Global Generic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is this Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. An Introduction to Generic Drugs
2.1 An Introduction to the Rise of Generic Drugs
2.2 What Are Generic Drugs?
2.2.1 Generic Active Ingredients
2.3 A Brief Overview of the Pharmaceutical Industry
2.3.1 Brief History of Generic Drugs
2.3.2 The Hatch-Waxman Act: The Rise of Generics
2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
2.5 Types of Generics – Authorised, Branded and Unbranded
2.6 Complex Generics
2.7 Classification of Generic Drugs Markets
2.8 Is Generic Substitution Bad News for Big Pharma Business?
2.8.1 The 'Ever greening' of Pharmaceutical Products
2.9 Regulation of Generic Drugs
2.9.1 Regulation in the US
2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs
2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
2.9.1.4 How Has the Hatch-Waxman Act Impacted upon the US Pharmaceutical Market?
2.9.1.5 How the Timing of Market Entry Influences Product Success
2.9.2 Regulation in Europe
2.9.2.1 EU Marketing Approval Procedures
2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity
2.9.2.3 Supplementary Protection Certificates
2.9.2.4 Variation in Drug Development Regulations between European Countries
2.9.2.5 The Move towards the Harmonisation of Standards
2.9.2.6 The Impact of Europe’s Unitary Patent System on Generic Drugs
2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
2.9.3 Regulation in Japan
2.9.4 Regulation in China
2.10 Compulsory Licensing
2.11 Market Definition and Scope of This Report
2.11.1 Market Sizing and Revenue Reporting
3. Generic Drugs Market 2017-2028
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting the Global Generic Drugs Market
3.2 The Rise of the Global Generic Drugs Market in 2018
3.3 The Global Generic Drugs Market: Sales Forecast 2017-2028
3.4 Generic Drugs: Regional Market Forecast: 2017-2028
3.4.1 Changes in Generic Drug Regional Market Shares 2017-2028
3.5 National Markets That Will Drive Generic Drugs Growth
3.6 Changes in Market Shares by National Market 2017-2028
3.7 Drivers and Restraints for the Global Generic Drugs Market 2017-2028
4. North America Generic Drugs Market, 2017-2028
4.1 Generic Drugs in the North America: Market Overview
4.1.1 The Hatch-Waxman Act and Its Ongoing Effects
4.1.2 Consolidation in the Drug Development and Supply Chain Driving North America Generics
4.2 North America Generic Drugs Market: Drivers and Restraints 2017-2028
4.3 North America Generic Drugs Market Forecast: 2017-2028
4.4 Leading Companies Operating within the North America Generic Drugs Market
4.4.1 Increasing Acceptance of Generics amongst Consumers
4.4.2 Affordable Care Act: Expanding Medicare Coverage
4.5 North America Generic Drugs Market – Strategic Analysis
4.5.1 Will Biosimilars Dictate the Future of the US Generics Market?
4.5.2 The Backlog of ANDA Applications
4.5.3 The Generic Drug User Fee Amendments (GDUFA)
4.5.4 Shortages of Generic Drugs Will Restrain the Market
4.5.5 The Anti-Competitive ‘Pay for Delay’ Effect
4.6 US Generic Drugs Market: A Range of Factors Contributing to Growth
4.7 Canada Generic Drugs Market: A Range of Factors Contributing to Growth
4.8 North America Generic Drugs Market: Market Share Analysis
5. Europe Generic Drugs Market, 2017-2028
5.1 Generic Drugs in the Europe: Market Overview
5.1.1 Why Growth in Some Markets is Being Hindered?
5.1.2 Predominant Pricing Systems and Generic Penetration in European Markets
5.1.2.1 Lower Patient Co-Payments Drive Demand for Generics
5.1.2.2 The Effects of Tendering for Generic Medicines
5.1.3 Will Europe Move towards Free-Pricing Systems?
5.1.4 Challenges in the European Regulatory Environment
5.1.5 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe
5.1.6 FDA and EMA Joint Data Sharing and Inspections
5.2 Europe Generic Drugs Market Forecast: 2017-2028
5.3 Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry
5.4 UK Generic Drugs Market: A Mature Market with Growth Potentials
5.4.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
5.5 France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
5.6 Italy Generic Drugs Market: Branded Generics Hindering Overall Growth
5.6.1 The Tightening of Italy’s Patent Legislations
5.6.2 The Italian Healthcare System – A Tale of Falling Budgets
5.7 Spain Generic Drugs Market: Room for Growth
5.7.1 Cost-Containment Measures Helping to Boost Generic Drug Use
5.8 Europe Generic Drugs Market: Market Share Analysis
6. Asia-Pacific Generic Drugs Market, 2017-2028
6.1 Generic Drugs in the Asia-Pacific Market: Market Overview
6.2 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
6.2.1 Leading Companies in the Indian Generic Drugs Market
6.2.2 Indian Generic Drugs Market: Sales Forecast 2017-2028
6.2.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
6.2.4 Expansion of the National Healthcare Coverage Increases the Need for Generics
6.2.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?
6.3 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
6.3.1 The Major Drivers of Growth in the Chinese Generics Market
6.3.2 Chinese Generic Drugs Market: Sales Forecast 2017-2028
6.3.3 Compulsory Licensing of Generic Drugs
6.3.4 Expansion of Healthcare Coverage and Reimbursement
6.3.5 The Impacts of Price Controls and the Anhui Model
6.4 Japanese Generic Drugs Market: High Barriers to Entry
6.4.1 Public Perception of Generics in Japan
6.4.2 Japanese Generic Drugs Market: Leading Companies
6.4.3 Government Initiatives Driving Generic Penetration
6.4.4 Japanese Attitudes to Generic Drugs
6.4.5 Japanese Generic Drugs Market: Sales Forecast 2017-2028
6.5 Australia Generic Drugs Market: Increased Market Access Supports the Market Growth
6.5.1 Australia Generic Drugs Market: Sales Forecast 2017-2028
6.6 South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth
6.6.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
6.6.2 KORUS FTA: The Free Trade Agreement between South Korea and the US
6.6.3 The Free Trade Agreement between Korea and the European Union
6.6.4 South Korean Generic Drugs Market: Sales Forecast 2017-2028
6.7 Asia-Pacific Generic Drugs Market: Market Share Analysis
7. Middle-East & Africa Generic Drugs Market, 2017-2028
7.1 Generic Drugs in the Middle-East & Africa Market: Market Overview
7.2 South Africa Generic Drugs Market:
7.2.1 South Africa Generic Drugs Market: Sales Forecast 2017-2028
7.3 Saudi Arabia Generic Drugs Market:
7.3.1 Saudi Arabia Generic Drugs Market: Sales Forecast 2017-2028
7.4 UAE Generic Drugs Market:
7.4.1 UAE Generic Drugs Market: Sales Forecast 2017-2028
7.5 Middle-East & Africa Generic Drugs Market: Market Share Analysis
8. Latin America Generic Drugs Market, 2017-2028
8.1 Generic Drugs in the Latin American Market: Market Overview
8.2 Brazil Generic Drugs Market:
8.2.1 Brazil Generic Drugs Market: Sales Forecast 2017-2028
8.3 Argentina Generic Drugs Market:
8.3.1 Argentina Generic Drugs Market: Sales Forecast 2017-2028
8.4 Mexico Generic Drugs Market:
8.4.1 Mexico Generic Drugs Market: Sales Forecast 2017-2028
8.5 Latin America Generic Drugs Market: Market Share Analysis
9. Leading Companies in the Generic Drugs Market, 2017-2028
9.1 Generic Drugs: Continuous Expansion to Rival
9.1.1 The Leading Companies in the Global Generics Market
9.2 Teva Pharmaceuticals Industries Limited
9.2.1 Teva: Historical Financial and Performance Analysis, 2013-2017
9.2.2 Teva Generic Drugs Sales Forecast 2017-2028
9.2.3 Teva acquired Allergan’s Generic Business Segment – Actavis Generic
9.2.3.1 Further Entry into the Japanese Generics Market
9.2.4 Teva: Generic Drugs Portfolio Analysis
9.2.4.1 High-Value Generics to Drive Teva’s Generics Growth?
9.2.4.2 The Shift towards Innovation
9.2.4.3 Copaxone Leads Teva’s Moving Focus
9.2.4.4 The Threat of Generic Erosion to Teva’s Products
9.2.4.5 Teva: What Future Moves Could We Expect?
9.3 Novartis
9.3.1 Novartis/Sandoz: Historical Financial and Performance Analysis, 2013-2017
9.3.2 Novartis/Sandoz Generic Drugs Sales Forecast 2017-2028
9.3.3 Novartis/Sandoz Generic Drugs Portfolio Analysis, 2017
9.3.3.1 Emphasis on Difficult-to-Manufacture Products
9.3.3.2 What Does the Future Hold for Novartis’ Generic Drugs Business?
9.4 Mylan
9.4.1 Mylan: Historical Financial and Performance Analysis, 2012-2016
9.4.2 Mylan Generic Drugs Sales Forecast 2017-2028
9.4.3 Mylan: Recent Developments
9.4.3.1 Acquisition of Meda AB
9.4.3.2 Acquisition of Abbott’s Generic Business
9.4.3.3 Mylan’s Growth in Manufacturing Capacity
9.4.3.4 Mylan Acquires Rights to GSK’s Advair, Diskus and Seretide
9.4.3.5 The Race to Market Copaxone Generics
9.4.3.6 Strategic Acquisition of Agila Expands Mylan’s Injectables Business
9.4.4 Mylan’s Collaborative Efforts
9.4.4.1 Biosimilar Collaboration with India’s Biocon
9.4.4.2 Biosimilar Collaborations with Momenta
9.4.4.3 What Does the Future Hold for Mylan’s Generic Drugs Business?
9.5 Pfizer
9.5.1 Pfizer: Historical Financial and Performance Analysis, 2012-2016
9.5.2 Pfizer’s Restructuring Strategy
9.5.3 Pfizer’s Done Deal with Hospira
9.5.4 Pfizer Generic Drugs Sales Forecast 2017-2028
9.5.5 Hospira: A Brief Overview of Operations
9.5.6 Hospira: Historical Financial and Performance Analysis 2011-2015
9.5.7 Hospira: Recent Developments
9.5.7.1 Hospira’s Expansion through Strategic Acquisitions
9.5.7.2 Hospira: Manufacturing Concerns and Remediation Efforts
9.5.8 Future Prospects for Pfizer’s Generic Business
9.5.8.1 The Pfizer-Allergan Deal Falls Through
9.5.8.2 Activities of Allergan (Actavis) Prior to Mega-Merger
9.5.8.3 Actavis’ Work on Biosimilars
9.6 Abbott
9.6.1 Abbott: Historical Financial and Performance Analysis, 2014-2016
9.6.2 Abbott Generic Drugs Sales Forecast 2017-2028
9.6.3 Abbott: Recent Developments
9.6.3.1 Abbott acquired St. Jude Medical
9.6.3.2 Abbott after the Spin-Off of AbbVie - The Established Products Business Segment
9.6.3.3 Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions
9.6.3.4 Acquisition of CFR Pharmaceuticals Opens New Markets
9.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?
9.7 Sun Pharma
9.7.1 Sun Pharma’s Business Areas
9.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2011-2015
9.7.3 Sun Pharma Generic Drugs Sales Forecast 2017-2028
9.7.4 Sun Pharma-Ranbaxy Acquisition
9.8 Aspen
9.8.1 Aspen: Historical Financial and Performance Analysis, 2012-2017
9.8.2 Aspen Generic Sales Forecast 2017-2028
9.8.3 Aspen: Recent Developments
9.8.3.1 Aspen Acquires Merck MSD’s Dutch API Plant
9.8.3.2 Acquisition of GSK’s Anti-Thrombosis Brands
9.8.3.3 Future Outlook for Aspen’s Generic Business
9.9 Fresenius Kabi
9.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2011-2015
9.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2017-2028
9.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
9.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health
9.9.5 Future Prospects for Fresenius Kabi’s Generics Business
9.10 Sanofi
9.10.1 Sanofi: Historical Financial and Performance Analysis, 2011-2015
9.10.2 Sanofi Generic Sales Forecast 2017-2028
9.10.3 Sanofi’s Response to Lantus Competition
9.10.4 Emerging Market Acquisitions
9.10.5 Future Prospects for Sanofi’s Generics Business
9.11 Dr. Reddy’s Laboratories Limited
9.11.1 Dr. Reddy’s: Historical Financial and Performance Analysis, 2015-2017
9.11.2 Dr. Reddy’s Generic Sales Forecast 2017-2028
9.11.3 Dr. Reddy’s launched generic Azacitidine for Injection in the Canadian Market
9.11.4 The company acquired Imperial Credit Private Limited, a Non-Banking Finance Company
9.11.5 Dr. Reddy’s expanded its operations in the European region
9.12 Apotex, Inc.
9.12.1 Apotex expanded its manufacturing facilities in the U.S.
9.12.2 Apotex launched first Generic Version of Merck's Nasonex
10. Qualitative Analysis of the Generic Drugs Market, 2017-2028
10.1 Market Factors Influencing the Global Generic Drugs Market
10.2 SWOT Analysis of the Global Generic Drugs Market, 2017-2028
10.2.1 Strengths
10.2.1.1 Improving Clarity around Regulatory Processes
10.2.1.2 The Continuous Government Support for Generic Manufacturers – Precursors for Innovation
10.2.1.3 Higher Pace of Growth Compared with Innovative Pharma
10.2.1.4 Globalisation and Its Impact on Manufacturing Capabilities
10.2.2 Weaknesses
10.2.2.1 Safety and Quality Concerns in the Manufacturing Process
10.2.2.2 The Non-Uniformity of Excipients
10.2.2.3 The Uncertainty around Patent Extensions and Exclusivities
10.2.2.4 Sceptical Physicians and the Negative Consumer Perception of Generics
10.2.2.5 Inefficiencies in Certain Regulatory Approval Processes
10.2.3 Opportunities
10.2.3.1 Higher Value Biosimilars and Branded Generics
10.2.3.2 Patent Expiries Creating Opportunities
10.2.3.3 Changing Socio-Economic Conditions Impacting Generic Drugs Demand
10.2.3.4 Emerging Markets – Expected to Drive Generics Volume Growth over Time
10.2.4 Threats
10.2.4.1 Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices
10.2.4.2 The Complexity Surrounding Patents and Patent Expiries
10.2.4.3 Pharmacies and Healthcare Payer Consolidations
10.2.4.4 Possible Impacts of a Declining Patent Pool
10.3 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017-2028
10.3.1 Power of Buyers: Medium
10.3.2 Power of Suppliers: Low
10.3.3 Rivalry among Competitors: High
10.3.4 Threat of New Entrants: High
10.3.5 Threat of Substitutes: Low
11. Conclusions
11.1 Overview of Current Market Conditions and Market Forecast, 2017-2028
11.1 Generic Drugs as a Strategic Tool in Healthcare
11.2 Major Drivers of Growth for Generic Drugs, 2017-2028
11.3 The Regulatory Landscape for Generic Drugs
11.4 Leading Generic Drug Manufacturers
11.5 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2017-2028
11.6 What Does the Future Hold for the Global Generic Drugs Market?
Appendices
Glossary
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Types of Drug Names, 2017
Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Regional and National Markets, 2017 and 2018
Table 3.2 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 3.3 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2017-2028
Table 3.4 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2017, 2022, and 2028
Table 3.5 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2022, 2022-2028, 2017-2028
Table 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2017, 2022, and 2028
Table 4.1 North America Generic Drugs Market: by Country Value ($bn), AGR (%), and CAGR (%), 2017 - 2028
Table 4.2 U.S. Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
Table 4.3 Canada Generic Drugs Market Value ($bn), AGR (%), CAGR (%), 2017 - 2028
Table 5.1 Europe Generic Drugs Market: by Country Value ($bn), AGR (%) and CAGR (%) 2017 - 2028
Table 5.2 Germany Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
Table 5.3 UK Generic Drugs Market Value ($bn), AGR (%) and CAGR (%) 2017 - 2028
Table 5.4 France Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
Table 5.5 Italy Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
Table 5.6 Spain Generic Drugs Market Value ($bn), AGR (%), and CAGR (%), 2017 - 2028
Table 6.1 India Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 6.2 Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2017, 2022 & 2028
Table 6.3 China Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 6.4 Japan Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 6.5 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 6.6 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 7.1 South Africa Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 7.2 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 7.3 UAE Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 8.1 Brazil Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 8.2 Argentina Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 8.3 Mexico Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2016 and 2017
Table 9.2 Teva: Company Overview
Table 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017
Table 9.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.5 Novartis: Overview
Table 9.6 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017
Table 9.7 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.8 Mylan: Company Overview
Table 9.9 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2016
Table 9.10 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.11 Pfizer: Company Overview
Table 9.12 Pfizer (Greenstone): Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2014-2016
Table 9.13 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.14 Hospira: Company Overview
Table 9.15 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
Table 9.16 Abbott: Company Overview
Table 9.17 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2016
Table 9.18 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.19 Sun Pharmaceuticals: Company Overview
Table 9.20 Sun Pharma: Historical Generic Drugs Sales ($bn), 2013-2017
Table 9.21 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.22 Aspen: Company Overview
Table 9.23 Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2013-2017
Table 9.24 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 9.25 Fresenius Kabi: Company Overview
Table 9.26 Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2011-2015
Table 9.27 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028
Table 9.28 Sanofi: Company Overview
Table 9.29 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 9.30 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028
Table 9.31 Dr. Reddy’s Laboratories Limited: Company Overview
Table 9.32 Dr. Reddy’s: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017
Table 9.33 Dr. Reddy’s Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028
Table 9.34 Apotex, Inc.: Company Overview
Table 10.1 SWOT Analysis of the Generic Drugs Market, 2017-2028
Table 11.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2017, 2022 and 2028
Table 11.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2017
Table 11.3 Global Generic Drugs Market Forecast: Revenue ($bn) by Regional Markets, 2017, 2022 and 2028

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report